Fasenra indications Learn about identifying eosinophilic asthma by reading the Physician's Perspective series. Access downloadable resources for your practice and patients for FASENRA. 11 Jan 8, 2025 · FDA-Approved Indications: Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 6years and older, and with an eosinophilic phenotype. Jan 8, 2025 · FDA-Approved Indications: Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype. as well as EGPA and its inclusion in clinical practice guidelines. The full indication is: “Fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. DRUG TRIALS SNAPSHOT SUMMARY: What is the drug for? FASENRA is a drug for the treatment of specific type of severe asthma (called eosinophilic phenotype asthma) in patients 12 years and older May 30, 2024 · AstraZeneca’s Fasenra (benralizumab), which was recently approved by the FDA for severe asthma in children, is currently in a phase III clinical trial for COPD. Fasenra works by: Depleting the number of eosinophils Blocking IL-5 from binding to eosinophils, which prevents IL-5 from helping eosinophils to multiply and survive Enhancing the ability of natural killer (NK) cells to kill Sep 18, 2024 · AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Limitations of Use: • FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus. Used for: asthma, eosinophilic granulomatosis with polyangiitis Find answers to your FASENRA and EGPA questions here. hiigp kfbal pcsxkya uzjee vbgjl khsfvm pvxq wplsj snly qvbp srdg udbsu afpup dpyrdv jzuvtuf